Incyte & Genmab Collaborate to Develop a New Colorectal Cancer TherapyZacks Investment Research · 2 hr ago
Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026Business Wire · 5 hr ago
Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal CancerGuruFocus · 2 days ago
Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal CancerBusiness Wire · 2 days ago
Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal CancerBusiness Wire · 2 days ago
Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal CancerGuruFocus · 2 days agoIncyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 28, 2026 | $2.15 | $3.09 | Beat |
| Apr 28, 2026 | $1.34 | $1.81 | Beat |
| Feb 10, 2026 | $1.90 | $1.80 | Miss |
| Oct 28, 2025 | $1.66 | $2.26 | Beat |
| Jul 29, 2025 | $1.39 | $1.57 | Beat |
| Apr 29, 2025 | $1.01 | $1.16 | Beat |